Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 9459Neoplasms 6577Prostatic Neoplasms 4394Colorectal Neoplasms 3964Lung Neoplasms 3633Carcinoma, Non-Small-Cell Lung 3576Pancreatic Neoplasms 2472Carcinoma, Hepatocellular 2407Leukemia, Myeloid, Acute 2261Multiple Myeloma 2115Stomach Neoplasms 2104Neoplasm Metastasis 1911Head and Neck Neoplasms 1864Ovarian Neoplasms 1770Precursor Cell Lymphoblastic Leukemia-Lymphoma 1732Lymphoma 1728Brain Neoplasms 1696Rectal Neoplasms 1672Melanoma 1652Colonic Neoplasms 1629Leukemia 1498Uterine Cervical Neoplasms 1493Recurrence 1480Esophageal Neoplasms 1309Glioblastoma 1303Lymphoma, Non-Hodgkin 1202Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1108Urinary Bladder Neoplasms 1077Lymphoma, Follicular 1067

Interventions

defactinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Phase IB × Clear all
NCT07318324 2026-01-06

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
31 enrolled
Gynecologic

Phase IB

Data powered by HemOnc (CC BY 4.0) Colophon âš¡